Related Experiment Video
Updated: Jun 24, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Drug interactions of tipranavir, a new HIV protease inhibitor
Judit Morello1, Sonia Rodriguez-Novoa, Inmaculada Jimenez-Nacher
1Pharmacokinetic Unit, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain.
Abstract:
Tipranavir is one of the latest approved HIV protease inhibitors. This non-peptidic molecule is an strong inducer of cytochrome P450 and has to be co-administered with low doses ritonavir as pharmacokinetic booster to achieve effective antiviral activity in vivo. As expected, significant drug interactions may occur in patients treated with tipranavir/ritonavir, including diminished exposure to some antiretroviral agents. Although a few interactions can be managed with adequate drug dosing others preclude to use these medications in combination.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics: Drug–Drug Interactions
Drug toxicity: Drug–Drug Interaction
Inhibitors of Viral Protein Synthesis
Inhibitors of Virion Maturation and Assembly
Antiviral Nucleoside Inhibitors

